<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425852</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2015-02</org_study_id>
    <nct_id>NCT02425852</nct_id>
  </id_info>
  <brief_title>A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis</brief_title>
  <acronym>ACTIVE</acronym>
  <official_title>A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PHASE : IV TYPE OF STUDY : With direct benefit. DESCRIPTIVE : Multicentre, randomized, open
      label study. INCLUSION CRITERIA : Acute severe ulcerative colitis. OBJECTIVES : To compare
      the efficacy and safety of early administration of the combination therapy with infliximab
      and azathioprine with steroids and azathioprine in patients with acute severe ulcerative
      colitis treated with intravenous steroids.

      STUDY TREATMENTS : All patients :

      Intravenous steroids (0.8 mg/kg/day of methylprednisolone or equivalent) for 5 days.

      Combination therapy arm:

      Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day.

      Azathioprine arm:

      Steroids tapering for 3 months and Azathioprine 2-2.5 mg/kg/day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NUMBER OF PATIENTS : 73 patients in each group i.e. a total of 146patients. RECRUITMENT
      PERIOD : 36 months STUDY DURATION : 12 months

      PRIMARY END POINT : Treatment failure is defined by:

        -  Absence of steroid-free remission at W52 according to the total Mayo Disease Activity
           Index score

        -  OR Absence of mucosal healing (Mayo endoscopic subscore 0-1)

        -  OR Adverse event leading to treatment interruption

        -  OR Colectomy

        -  OR Death

        -  OR Infliximab withdrawal in the combination therapy group OR Infliximab introduction in
           the azathioprine group SECONDARY END POINT: - Clinical response and remission at D7, W14
           and W52 (according to Lichtiger score and total Mayo Disease Activity Index score)

        -  Endoscopic and histological response

        -  Mucosal healing (partial endoscopic Mayo subscore 0)

        -  Colectomy rate

        -  Adverse events rate

        -  Fecal calprotectin

        -  Health-economic outcome
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with treatment failure at week 52.</measure>
    <time_frame>Week 52</time_frame>
    <description>Failure is defined as:
absence of steroid-free remission (Total Mayo Disease Activity Index (DAI) score ≤ 2 with no individual subscore &gt; 1)
absence of mucosal healing (Endoscopic Mayo DAI subscore ≤ 1)
or severe adverse event leading to treatment interruption between day 0 and week 52
or colectomy between day 0 and week 52
or fatality between day 0 and week 52
or infliximab withdrawal for failure and /or intolerance in the combination therapy group
or any biological agent introduction in the azathioprine group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in clinical response at day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of patients in clinical response at day 7 (Lichtiger Index score&lt;10 with a decrease of at least 3 points compared with the baseline score) and at week 14 and week 52 (a decrease from baseline in the Mayo score ≥30% and ≥3 points, accompanied by either a rectal bleeding subscore of 0 or 1 or a decrease from baseline in the rectal bleeding subscore ≥1)
- Percentage of patients in clinical remission at day 7, week 14 and week 52</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Combination therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.
In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Azathioprine alone versus Azathioprine and IFX</description>
    <arm_group_label>Azathioprine arm</arm_group_label>
    <arm_group_label>Combination therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <arm_group_label>Combination therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Azathioprine arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <arm_group_label>Azathioprine arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Diagnosis of UC according to Lennard-Jones criteria (Appendix 1).

          -  Endoscopically demonstrated colorectal lesions localized above the anal margin and
             extending at least up to 15cm proximally (Endoscopic Mayo subscore ≥ 2).

          -  Acute flare requiring hospitalization

          -  Severe acute flare of UC with a Lichtiger Index score &gt; 10 at Day -3

          -  Adequate contraception for male or female subjects of childbearing potential, which
             will be continued throughout the study and at least 3 months after study termination.

        3.2 EXCLUSION CRITERIA

          -  Pregnant or breast-feeding woman.

          -  Previous treatment with infliximab.

          -  Treatment with adalimumab or golimumab within 8 weeks before randomization

          -  Treatment with vedolizumab within 4 weeks before randomization

          -  Azathioprine or 6-mercaptopurine treatment initiated more than 4 weeks before
             screening.

          -  Ongoing intravenous steroids for more than 96 hours at time of the screening

          -  Contraindication for anti-TNF therapy

          -  Indication for immediate surgery.

          -  History of colorectal dysplasia.

          -  Diagnosis of Crohn's disease or indeterminate colitis

          -  Positive stool tests for amoebiasis and/or positive bacteriological culture for
             Salmonella, Shigella, Yersinia and Campylobacter and/or presence of Clostridium
             difficile B toxin in the stools.

          -  Renal failure (creatininemia &gt; upper limit of normal laboratory value).

          -  Uncontrolled high blood pressure.

          -  HIV, HBV viral infection (except the presence of positive anti-HBs antibodies) with
             serology not older than 3 months.

          -  Uncontrolled bacterial or active viral infection.

          -  Past medical history of malignant condition in the last 5 years (including leukaemia,
             lymphoma and myelodysplasia) except for baso-cellular cutaneous cancers.

          -  Past medical history of myocardial infarction or heart failure.

          -  Intradermal reaction to Tuberculin (Tubertest® 5 units) &gt; 5mm or positive
             interferon-gamma release assay (Quantiferon®)

          -  Active tuberculosis

          -  Untreated latent tuberculosis (see national recommendations. Appendix 2).

          -  Abnormal blood count with polynuclear neutrophils &lt; 1,500 G/L or white cells &lt; 3,000,
             or platelets &lt; 100,000 G/L.

          -  Unexplained rise higher than 3 times the normal level for transaminases, alkaline
             phosphatases and/or higher than twice the normal level for bilirubin.

          -  Severe acute or chronic medical or psychiatric condition that may increase the risk
             associated with study participation or investigational product administration or may
             interfere with the interpretation of study results and, in judgement of the
             investigator, would make the subject inappropriate for entry in this study.

          -  Subjects who, in the opinion of the investigator, will be uncooperative or unable to
             comply with study procedures.

          -  Participation in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélien Amiot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Peyrin-Biroulet, MD , PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justine POLLET</last_name>
    <email>jpollet@getaid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUCINE VUITON, MD</last_name>
    </contact>
    <investigator>
      <last_name>LUCINE VUITON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>STEPHANE KOCH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de CLERMONT FERRAND- Hopital Estain</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony BUISSON, MD</last_name>
      <email>abuissonr@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anthony BUISSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital BEAUJON</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <email>yoram.bouhnik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Mourrier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit COFFIN, MD,PhD</last_name>
      <phone>+33147606061</phone>
      <email>benoit.coffin@lmr.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit COFFIN, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline JOUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc SABATE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JEAN CHARLES DELCHIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FRANCK CARBONNEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin PARIENTE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin PARIENTE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROMAIN ALTWEGG, MD</last_name>
      <phone>+33467337394</phone>
    </contact>
    <investigator>
      <last_name>ROMAIN ALTWEGG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUILLAUME PINETON DE CHAMBRUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de NICE- Hopital Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEROME FILLIPI, MD</last_name>
      <email>filippi.j@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>JEROME FILLIPI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XAVIER HEBUTERNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu ALLEZ, MD, PhD</last_name>
      <phone>33 1 42 49 95 97</phone>
      <email>matthieu.allez@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu ALLEZ, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc GORNET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion SIMON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques COSNES, MD, PhD</last_name>
      <phone>+33 1 49 28 31 70</phone>
      <email>jacques.cosnes@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe SEKSIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BEAUGERIE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELISE CHANTELOUP, MD</last_name>
      <email>echanteloup@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>ELISE CHANTELOUP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU RENNES - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
    </contact>
    <contact_backup>
      <email>guillaume.bouguen@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIE DEWITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LEREBOURS, MD,PhD</last_name>
      <phone>+33232888101</phone>
      <email>eric.lerebours@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LEREBOURS, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume SAVOYE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>St Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ROBLIN, MD</last_name>
      <phone>+33 4 77 82 83 20</phone>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier ROBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hopital Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURENT PEYRIN BIROULET, MD,PhD</last_name>
      <phone>+33383153354</phone>
      <email>peyrinbiroulet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laurent PEYRIN-BIROULET, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille ZALLOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

